眼科

• 论著 • 上一篇    下一篇

曲安奈德球侧及上穹隆部注射治疗中重度活动期甲状腺相关眼病的效果

罗丽华1  高立新1  王薇1  苗慧1  马秀梅1  李冬梅2   

  1. 1首都医科大学附属北京友谊医院眼科 100050;2首都医科大学附属北京同仁医院 北京同仁眼科中心  眼科学与视觉科学北京市重点实验室 100730
  • 收稿日期:2020-01-14 出版日期:2020-07-22 发布日期:2020-07-21
  • 通讯作者: 李冬梅,Email:ldmlily@x263.net
  • 基金资助:
    北京市医院管理中心儿科学科协同发展中心专项(XTCX201824);首都卫生发展科研专项项目(CFH 2018-2-2053);首都医科大学附属北京友谊医院院启动基金(yyqdkt2018-33)

Efficacy of triamcinolone periglobal and upper fornix injection for moderate to severe active thyroid associated ophthalmopathy

Luo Lihua1, Gao Lixin1, Wang Wei1, Miao Hui1, Ma Xiumei1, Li Dongmei2   

  1. 1 Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 2Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
  • Received:2020-01-14 Online:2020-07-22 Published:2020-07-21
  • Contact: Li Dongmei, Email: ldmlily@x263.net
  • Supported by:
    The Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority (XTCX201824); Capital’s Funds for Health Improvement and Research (CFH 2018-2-2053); Research Foundation of Beijing Friendship Hospital, Capital Medical University (yyqdkt2018-33)

摘要: 目的 观察曲安奈德(triamcinolone acetonide,TA)球侧及上穹隆部注射治疗中重度活动期甲状腺相关眼病(thyroid associated ophthalmopathy,TAO)的疗效与并发症。设计 回顾性病例系列。 研究对象 北京友谊医院中重度活动期TAO 患者34例(60眼)。方法 回顾患者的病历资料。所有患者采用眼球侧注射TA(20~40 mg)。其中上睑退缩≥2 mm者联合上睑穹隆部注射TA(20 mg)。首次治疗后1周复查,此后每月复查,如症状改善,每月重复注射1次。当上睑位置降至正常或与对侧健眼一致,眼睑、结膜充血水肿、复视消退时停药。观察随访至少3个月,平均随访(9.12±5.28)个月。主要指标 临床活动性评分(clinical activity score,CAS)、甲状腺眼病生活质量量表(quality of life in thyroid eye disease,TED-QOL)评分,上睑缘距角膜映光点距离(marginal reflex distance,MRD1)、眼球突出度、最佳矫正视力、眼压、B超眼外肌直径。结果 治疗前及最后随访时比较,CAS评分分别为(3.79±0.81)、(1.29±0.68)(P=0.000);TED-QOL量表评分分别为(17.85±2.80)、(10.18±3.02)(P=0.000);MRD1分别为(6.29±0.68)、(4.56±0.71)(P=0.000);眼球突出度分别为(18.20±2.77)mm、(17.65±2.90)mm(P=0.000);上、下、内、外直肌直径分别为(2.34±0.67、3.62±1.06、3.06±0.67、2.71±0.79)mm,(2.15±0.50、3.30±0.99、2.81±0.61、2.51±0.61)mm(P均<0.05);最佳矫正视力(LogMAR)分别为(4.99±0.12)、(4.99±0.16)(P=0.289);眼压分别为(16.65±2.91)mmHg、(16.78±4.30)mmHg(P=0.772)。上睑退缩者球侧注射联合上穹隆注射组较单纯球侧注射组的上睑退缩程度治疗前后差异分别为(1.15±0.38)mm、(2.31±0.48)mm(P=0.000);两组眼球突出度前后差异分别为(-0.69±0.75)、(-0.84±1.28)mm(P=0.712);两组治疗前后上、下、内、外直肌直径差分别为(0.22±0.52,0.28±0.49)mm,(0.32±0.56,0.51±0.76)mm、(0.35±0.40,0.34±0.49)mm,(0.23±0.56,0.47±0.84)mm(P均>0.05)。治疗后眼压升高>21 mmHg者9/60眼(15%)。治疗后月经改变2例。结论 40 mgTA眶周注射可有效降低活动期TAO眶部的炎性反应。球侧及上穹隆部联合注射较单纯球侧注射对上睑退缩改善更明显。治疗同时要注意眼压升高等并发症。(眼科,2020,29:260-265)
     

关键词: 甲状腺相关眼病/治疗, 曲安奈德

Abstract:  Objective To study the efficacy and complication of triamcinolone (TA) periglobal and upper fornix injection for moderate to severe active thyroid associated ophthalmopathy (TAO).  Design Retrospective case series. Participants 34 cases (60 eyes) of patients with moderate to severe TAO. Methods The patient's medical records were reviewed. All patients received a periobital injection of  TA (20-40 mg). The patients whose upper eyelid retraction ≥2 mm were given 20 mg TA into the fornix of the upper eyelid. Follow-up visit at 1 week after the first treatment, repeat the injection monthly if the symptoms were improved. When the upper eyelid position dropped to normal or consistent with the contralateral eye, the eyelid and conjunctival hyperemia and edema were stopped, the patients were observed and followed up for at least 3 months. The mean follow-up was 9.12±5.28 months. Main Outcome Measures Clinical activity score (CAS), thyroid eye disease quality of life scale (TED-QOL), marginal reflex distance(MRD1), exophthalmos, LogMAR best corrected visual acuity (BCVA), intraocular pressure, B ultrasonic extraocular muscle diameter. Results Before treatment and in the last follow-up, the CAS scores were (3.79±0.81) and (1.29±0.68)  respectively (P=0.000). The TED-QOL scale scores were (17.85±2.80) and (10.18±3.02) respectively (P=0.000). The MRD1 was (6.29±0.68) and (4.56±0.71) respectively (P=0.000). The degree of exophthalmos was (18.20±2.77)mm  and (17.65±2.90) mm respectively (P=0.000). The diameters of the superior, inferior, internal and external rectus muscles were (2.34±0.67, 3.62±1.06, 3.06±0.67, 2.71±0.79)mm, (2.15±0.50, 3.30±0.99, 2.81±0.61, 2.51±0.61)mm, respectively (all P<0.05). The BCVA (LogMAR) was (4.99±0.12) and (4.99±0.16) (P=0.289) respectively. Intraocular pressure was (16.65±2.91)mmHg and (16.78±4.30)mmHg respectively (P=0.772). The difference in the degree of upper eyelid retraction between periglobal and upper fornix injection and single periglobal injection was (1.15±0.38) mm and (2.31±0.48)mm respectively (P=0.000). The difference before and after treatment of exophthalmos between the two groups was (-0.69±0.75) mm and (-0.84±1.28)mm respectively (P=0.712). The difference before and after treatment of upper, lower, internal and external rectus muscles in the two groups were (0.22±0.52, 0.28±0.49)mm, (0.32±0.56, 0.51±0.76)mm, (0.35±0.40, 0.34±0.49)mm, and (0.23±0.56, 0.47±0.84)mm, respectively (all P>0.05). Intraocular pressure of 9/60 eyes (15%) had increased >21 mmHg after treatment. Menstrual changes were observed in 2 cases. Conclusions Periorbital injection of 40 mg TA can effectively reduce the orbital inflammation of TAO in active stage. The improvement of upper eyelid retraction in periglobal combined with upper fornix injection was more obvious than that of single periglobal injection. At the same time, the complications such as increased intraocular pressure should be paid attention. (Ophthalmol CHN, 2020, 29: 260-265)

Key words:  thyroid-associated ophthalmopathy/treatment, triamcinolone